Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for MEDBOT-B?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2019–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Net income was negative in FY2019, FY2020, FY2021, FY2022, FY2023, FY2024, FY2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 0.00 | 0.02 | 0.10 | 0.26 | 0.55 |
| YoY | — | 904.8% | 384.2% | 146.0% | 114.2% |
| Net Income (CNY B) | -0.58 | -1.14 | -1.01 | -0.64 | -0.25 |
| Operating Cash Flow (CNY B) | -0.54 | -0.90 | -0.57 | -0.30 | -0.02 |
| ROE | -30.4% | -59.8% | -104.5% | -161.1% | -72.5% |
| Gross Margin | 42.7% | 30.4% | 14.0% | 33.5% | 48.4% |
| Net Margin | -27112.6% | -5276.1% | -967.7% | -249.7% | -45.3% |
| Debt-to-Assets | 14.4% | 27.1% | 64.9% | 79.9% | 70.0% |
Show all 7 fiscal years
| Fiscal Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | — | 0.00 | 0.00 | 0.02 | 0.10 | 0.26 | 0.55 |
| YoY | — | — | — | 904.8% | 384.2% | 146.0% | 114.2% |
| Net Income (CNY B) | -0.07 | -0.21 | -0.58 | -1.14 | -1.01 | -0.64 | -0.25 |
| Operating Cash Flow (CNY B) | -0.05 | -0.10 | -0.54 | -0.90 | -0.57 | -0.30 | -0.02 |
| ROE | -264.3% | -28.4% | -30.4% | -59.8% | -104.5% | -161.1% | -72.5% |
| Gross Margin | — | — | 42.7% | 30.4% | 14.0% | 33.5% | 48.4% |
| Net Margin | — | — | -27112.6% | -5276.1% | -967.7% | -249.7% | -45.3% |
| Debt-to-Assets | 66.3% | 15.4% | 14.4% | 27.1% | 64.9% | 79.9% | 70.0% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Alert
-
Alert
Net LossesGoing Concern
FY2025 (2025-12-31) CN¥-0.25B, FY2024 (2024-12-31) CN¥-0.64B
FY2025 (ended 2025-12-31)
-
Alert
Delayed Financial ResultsMaterial Events
-
Alert
Trading SuspensionMaterial Events
-
Watch
Receivables DaysFinancial Quality
174.7 days, prior FY 131.7 days(+33%)
FY2025 (ended 2025-12-31) · What is this?
- Watch
-
Watch
High Cash & High DebtSolvency
cash 47.7% of assets, total debt 29.2% of assets
FY2025 (ended 2025-12-31)
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
No dividends paid over the trailing 12 months.
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.